Article
Effect of CYP2C9 and VKORC1 Gene Variants on Warfarin Response in Patients with Continuous-Flow Left Ventricular Assist Devices.
ASAIO journal (American Society for Artificial Internal Organs : 1992) - 1 Jan 2000
Topkara Veli K, Knotts Robert J, Jennings Douglas L, Garan A Reshad, Levin Allison P, Breskin Alexander, Castagna Francesco, Cagliostro Barbara, Yuzefpolskaya Melana, Takeda Koji, Takayama Hiroo, Uriel Nir, Mancini Donna M, Eisenberger Andrew, Naka Yoshifumi, Colombo Paolo C, Jorde Ulrich P
Abstract excerpt
Bleeding and thrombotic complications continue to plague continuous-flow left ventricular assist device (CF-LVAD) therapy in patients with end-stage heart failure. Warfarin genotyping information can be incorporated into decision making for initial dosing as recommended by the Food and Drug Administration; however, clinical utility of this data in the CF-LVAD population has not been well studied. Genotypes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
